ErbB3-binding protein 1 inhibits tumor proliferation in esophageal cancer by targeting bcl-2 and p53 gene.

Peiliang Zhang, Shanlan Yang, Shuren Cao, Baosheng Li

Open access · greenAbstract read

In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 79% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Peiliang ZhangInstitute of Radiotherapy, Linyi Central Hospital Shandong Province, China.

Shanlan YangInstitute of Radiotherapy, Linyi Central Hospital Shandong Province, China.

Shuren CaoInstitute of Radiotherapy, Linyi Central Hospital Shandong Province, China.

Baosheng LiDepartment of Radiotherapy, Shandong Tumor Hospital Shandong Province, China.

Linyi People's Hospital · CNShandong Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cnacer is one of the common malignant tumors with high fatality rate and morbidity, ErbB3-binding protein 1 (EBP1) is the intracellular binding protein of ErbB3. This study aims to investigate the effect of EBP1 on esophageal cancer biological behavior and the underlying mechanism. In our study, esophageal cancer tissues and adjacent non-tumor issues were collected and the relative expression of EBP1 mRNA were examined by real-time PCR. EBP1 mimics is synthesised and transfected onto Eca109 cells. The effects of EBP1 on biological behaviors of Eca109 cells were detected by colony formation assay and flow cytometry, the expression of bcl, p53 proteins were detected by western-blot. The results showed that EBP1 was down-regulation in NSCLC. The number of colony-forming units, and the tumor size and volume in vivo in the Eca109/EBP1 group was obviously lower and the apoptosis rate was significantly higher than the Eca109/NC group and Normal group (

Indexed as

apoptosisEBP1esophageal cnacerproliferationtumorigensis

Identifiers

PMID31966354

PMCPMC6965776

OpenAlexW3027622857

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.